Neurocrine Biosciences Inc Liquidation Value

NBIX Other

Cash & Equivalents

$713.00M
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $713.00M
Total Obligations: -$1.21B
$-501.70M
Per share: $-5.01
Period: 2025-12-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $713.00M
AR: $686.80M
Total Obligations: -$1.21B
$185.10M
Per share: $1.85
Period: 2025-12-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $713.00M
AR: $686.80M
Inventory: $69.00M
Total Obligations: -$1.21B
$254.10M
Per share: $2.54
Period: 2025-12-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-501.70M$-5.01
Liquid Liquidation Value$185.10M$1.85
Operating Liquidation Value$254.10M$2.54

Key Components (as of 2025-12-31)

Cash & Equivalents$713.00M
Accounts Receivable$686.80M
Inventory$69.00M
Current Liabilities$743.40M
Long-term Debt$170.40M
Op. Lease Liability$471.30M
Finance LeaseN/A
Shares Outstanding100.1M

Explore all 214 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$713.00M$686.80M$69.00MN/A$743.40MN/A$471.30MN/A
2025-09-30$340.20M$728.00M$69.30MN/A$638.00MN/A$479.70MN/A
2025-06-30$264.00M$595.70M$56.90MN/A$546.30MN/A$489.80MN/A
2025-03-31$194.10M$516.00M$59.10MN/A$522.90MN/A$493.10MN/A
2024-12-31$233.00M$479.10M$57.40MN/A$507.70MN/A$495.70MN/A
2024-09-30$349.10M$481.10M$45.80MN/A$429.70MN/A$286.20MN/A
2024-06-30$139.70M$468.20M$42.50MN/A$398.50MN/A$291.60MN/A
2024-03-31$396.30M$450.70M$37.20MN/A$712.90M$170.40M$287.90MN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-02-11 View
2025-09-30 10-Q 2025-10-28 View
2025-06-30 10-Q 2025-07-30 View
2025-03-31 10-Q 2025-05-05 View
2024-12-31 10-K 2025-02-10 View
2024-09-30 10-Q 2024-10-30 View
2024-06-30 10-Q 2024-08-01 View
2024-03-31 10-Q 2024-05-01 View

Community Notes

Loading notes...

Questions

Loading questions...